VistaGen Therapeutics (NASDAQ:VTGN) Posts Earnings Results

VistaGen Therapeutics (NASDAQ:VTGN) posted its quarterly earnings data on Friday. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.06, FiscalAI reports. The business had revenue of $1.48 million for the quarter, compared to analysts’ expectations of $0.50 million. VistaGen Therapeutics had a negative return on equity of 133.02% and a negative net margin of 5,487.01%.

VistaGen Therapeutics Stock Up 0.5%

NASDAQ:VTGN opened at $0.27 on Friday. The company has a market cap of $11.88 million, a P/E ratio of -0.15 and a beta of 0.41. VistaGen Therapeutics has a fifty-two week low of $0.20 and a fifty-two week high of $5.14. The firm’s 50 day moving average is $0.37 and its two-hundred day moving average is $0.51.

Institutional Trading of VistaGen Therapeutics

Several institutional investors have recently made changes to their positions in VTGN. Cubist Systematic Strategies LLC purchased a new position in shares of VistaGen Therapeutics in the 1st quarter worth $25,000. Schonfeld Strategic Advisors LLC purchased a new stake in VistaGen Therapeutics during the third quarter valued at about $39,000. Millennium Management LLC purchased a new stake in VistaGen Therapeutics during the third quarter valued at about $73,000. Bank of America Corp DE increased its stake in VistaGen Therapeutics by 1,068.0% during the fourth quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock worth $62,000 after acquiring an additional 19,331 shares during the last quarter. Finally, Marshall Wace LLP acquired a new stake in VistaGen Therapeutics during the second quarter worth about $69,000. 78.39% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of VistaGen Therapeutics in a research note on Wednesday, June 3rd. Four investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, VistaGen Therapeutics has a consensus rating of “Reduce” and a consensus target price of $0.95.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.